Aspirin Inhibits Colon Cancer Cell and Tumor Growth and Downregulates Specificity Protein (Sp) Transcription Factors
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Acetylsalicylic acid (aspirin) is highly effective for treating colon cancer patients postdiagnosis; however, the mechanisms of action of aspirin in colon cancer are not well defined. Aspirin and its major metabolite sodium salicylate induced apoptosis and decreased colon cancer cell growth and the sodium salt of aspirin also inhibited tumor growth in an athymic nude mouse xenograft model. Colon cancer cell growth inhibition was accompanied by downregulation of Sp1, Sp3 and Sp4 proteins and decreased expression of Sp-regulated gene products including bcl-2, survivin, VEGF, VEGFR1, cyclin D1, c-MET and p65 (NFκB). Moreover, we also showed by RNA interference that β-catenin, an important target of aspirin in some studies, is an Sp-regulated gene. Aspirin induced nuclear caspase-dependent cleavage of Sp1, Sp3 and Sp4 proteins and this response was related to sequestration of zinc ions since addition of zinc sulfate blocked aspirin-mediated apoptosis and repression of Sp proteins. The results demonstrate an important underlying mechanism of action of aspirin as an anticancer agent and, based on the rapid metabolism of aspirin to salicylate in humans and the high salicylate/aspirin ratios in serum, it is likely that the anticancer activity of aspirin is also due to the salicylate metabolite.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136 · cited 3×
“Aspirin and other NSAIDs reduce the incidence and increase survival of colon cancer patients and similar results have been observed for aspirin as a chemotherapeutic agent for treatment of breast cancer patients [4–8].”
BackgroundResultAspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557 · cited 3×
“Other drugs including NSAIDs such as tolfenamic acid and COX-2 inhibitors also inhibit cancer cell growth and downregulate Sp transcription factors [18–26] and, in this study, we have investigated the effects of aspirin on Sp proteins and other Sp-regulated genes including b-catenin.”
BackgroundInfluentialAspirin Intake and Survival After Breast Cancer
Holmes, M. D., Chen, W. Y., Li, L., Hertzmark, E., Spiegelman, D., & Hankinson, S. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7918 · Cited by 365 · cited 3×
“Aspirin and other NSAIDs reduce the incidence and increase survival of colon cancer patients and similar results have been observed for aspirin as a chemotherapeutic agent for treatment of breast cancer patients [4–8].”
BackgroundResultA Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence
Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., & Calle, E. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk132 · Cited by 322 · cited 2×
“Aspirin and other NSAIDs reduce the incidence and increase survival of colon cancer patients and similar results have been observed for aspirin as a chemotherapeutic agent for treatment of breast cancer patients [4–8].”
BackgroundResultChintharlapalli, S., Papineni, S., Ramaiah, S. K., & Safe, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3735 · Cited by 297 · cited 1×
“Moreover, several anticancer agents including NSAIDs and GT-094 (a NO-NSAID), curcumin, betulinic acid and synthetic triterpenoids, and arsenic trioxide decrease expression of Sp1, Sp3, Sp4 and Sp-regulated genes in cancer cells and these effects contribute to their anticancer activity [17,18,20,35].”
BackgroundSelf-citationEffect of aspirin and NSAIDs on risk and survival from colorectal cancer
Din, F. V. N., Theodoratou, E., Farrington, S. M., Tenesa, A., Barnetson, R. A., Cetnarskyj, R., Stark, L., Porteous, M. E., Campbell, H., & Dunlop, M. G. (2010) · Gut · doi:10.1136/gut.2009.203000 · Cited by 284 · cited 1×
“A recent report on the chemopreventive effects of aspirin showed that the incidence of colon cancer in Scotland was significantly decreased in the general population at the lowest daily dose of aspirin (75 mg) and the decreased incidence was observed even after only 5 yr of aspirin use [7].”
BackgroundAspirin, salicylates, and cancer
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A., & Morgan, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60243-9 · Cited by 282 · cited 4×
“Based on the similar effects of aspirin and salicylate as anticancer agents observed in Figures 1, 2, 3 and other studies [3,10,11,40] and the high serum salicylate/aspirin ratios [27], the cancer chemotherapeutic effects of aspirin observed in human cancer studies [3–5,7,8] may primarily be due to the salicylate meta…”
BackgroundResultInfluentialAbdelrahim, M., Smith, R., Burghardt, R., & Safe, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0713 · Cited by 199 · cited 2×
“RNA interference studies in several cancer cell lines show that knockdown of Sp1, Sp3 and Sp4 (singly or in combination) results in decreased expression of growth promoting (EGFR, c-MET, cyclin D1), survival (bcl-2, survivin), angiogenic (VEGF and its receptors), and pro-inflammatory [p65 (NFkB)] genes or gene product…”
BackgroundSelf-citationJutooru, I., Chadalapaka, G., Lei, P., & Safe, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.095240 · Cited by 178 · cited 8×
“Previous studies by RNA interference (RNAi) show that both survivin and bcl-2 are regulated by Sp1, Sp3 and Sp4 in cancer cells [17,22,24–26].”
BackgroundResultInfluentialSelf-citationTolfenamic Acid and Pancreatic Cancer Growth, Angiogenesis, and Sp Protein Degradation
Abdelrahim, M., Baker, C. H., Abbruzzese, J. L., & Safe, S. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj232 · Cited by 174 · cited 1×
“Moreover, several anticancer agents including NSAIDs and GT-094 (a NO-NSAID), curcumin, betulinic acid and synthetic triterpenoids, and arsenic trioxide decrease expression of Sp1, Sp3, Sp4 and Sp-regulated genes in cancer cells and these effects contribute to their anticancer activity [17,18,20,35].”
BackgroundSelf-citation
Cited by
Items 101–130 of 130
Chiang, S.-F., Tsai, M.-H., Tang, R., Hsieh, L., Chiang, J., Yeh, C.-Y., Hsieh, P., Tsai, W., Liu, Y.-P., Liang, Y. J., et al. (2014) · Surgical Science · doi:10.4236/ss.2014.510067 · Cited by 9
de Souza, D. F., Tsering, T., Burnier, M. N., Bravo-Filho, V., Dias, A. B. T., Abdouh, M., Goyeneche, A. A., & Burnier, J. V. (2020) · Ocular Oncology and Pathology · doi:10.1159/000510582 · Cited by 7
Karelia, D. N., Kim, S., Plano, D., Sharma, A. K., Jiang, C., & Lü, J. (2022) · The Prostate · doi:10.1002/pros.24430 · Cited by 7
Matos, A. L. D. S. A., Ovens, A. J., Jakobsen, E., Iglesias‐Gato, D., Bech, J. M., Friis, S., Bak, L. K., Madsen, G. I., Oakhill, J. S., Puustinen, P., et al. (2025) · Cells · doi:10.3390/cells14040294 · Cited by 6
Mohamed‐Ezzat, R. A., Kariuki, B. M., & Srour, A. M. (2023) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989023008526 · Cited by 9
Aspirin use and prostate tumor angiogenesis
Fu, B. C., Wang, K., Mucci, L. A., Clinton, S. K., & Giovannucci, E. L. (2021) · Cancer Causes & Control · doi:10.1007/s10552-021-01501-6 · Cited by 6
Lizeth, G.-R., Gustavo, M.-Q., Herrera-R, A., Castrillón-L, W., Yepes, A. F., & Cardona‐Galeano, W. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.120203 · Cited by 6
“It is important to notice that these hybrid compounds increased activity and selectivity through time, which is consistent with previous reports with the parental compound aspirin where different authors also suggest that aspirin acts in a time-dependent manner (Lai et al., 2008; Satya et al., 2012; Zhang et al., 2018…”
ResultZinc-containing derivatives of 2-aminopyrimidine
Орлов, А. П., Трофимова, Т. П., Osipova, E. Y., Proshin, A. N., & Орлова, М. А. (2017) · Russian Chemical Bulletin · doi:10.1007/s11172-017-1958-6 · Cited by 5
Mohapatra, T. K., Mohapatra, D., & Subudhi, B. B. (2019) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.53.4s.163 · Cited by 4
Preciado, D., Moreno, G., Cardona, W., & Yepes, A. F. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.121102 · Cited by 4
“As for ASA, its metabolite salicylic acid (SA), displayed antiproliferative and proapoptotic effects in CRC in in vitro and in vivo models (Brennan et al., 2021; Deb et al., 2011; Elder et al., 1996; Elder and Paraskeva 1999; Giardina and Inan, 1998; Gökçe et al., 2017; Pathi et al., 2012; Paterson and Lawrence, 2001).”
Barber, L. E., Bertrand, K. A., Li, S., White, L. F., Roy, H. K., Rosenberg, L. A., Palmer, J. R., & Petrick, J. L. (2023) · International Journal of Cancer · doi:10.1002/ijc.34674 · Cited by 3
“54 A limitation of the present analysis is that we were unable to assess frequency of medication use or medication dose, which would have clinical importance for informing recommendations for chemo-preventive use.”
Kawulok, A., Borzdziłowska, P., Głowala‐Kosińska, M., Fidyk, W., Smagur, A., Łasut-Szyszka, B., Gdowicz‐Kłosok, A., Mitrus, I., Wilkiewicz, M., Chwieduk, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136212 · Cited by 3
Takakura, H., Horinaka, M., Imai, A., Aono, Y., Nakao, T., Miyamoto, S., Iizumi, Y., Watanabe, M., Narita, T., Ishikawa, H., et al. (2021) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.21-74 · Cited by 3
“(6,7) Several studies (8,9) showed that salicylic acid has inhibitory effects on cell growth in human CRC cell lines.”
Effect of Aspirin on Nuclear β-Catenin Expression in Sporadic Colorectal Adenomas
Kim, H. J., Lee, S. J., Park, S. C., Choi, D. H., Kang, C. D., & Kang, G. (2013) · Intestinal Research · doi:10.5217/ir.2013.11.4.283 · Cited by 1
“대장암 세포주를 이용한 이전 연구들에서 아스피린이 β-catenin의 발현을 억제한다는 보고들이 있었다.(43,44) 인체조직을 이용한 이번 연구에서 그와는 다른 결과가 관찰된 원인에 대해 생각하면 첫 째, 대상 환자들의 아스피린의 복용 기간이 아스피린의 효과가 나타 나기에는 충분치 않을 수 있다는 점이다.”
Self-citationBurn, J., & Sheth, H. J. (2018) · Wiley eBooks · doi:10.1002/9781118990957.ch14 · Cited by 1
Zheng, B., Geng, Y., Li, Y., Huang, H., & Liu, A. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05764-2 · Cited by 1
“Sp1 and Sp3 tran - scription factors are expressed in different cancers [ 36]. β-catenin is a gene regulated by Sp proteins [ 37].”
ROLES OF INOSITOL DIPHOSPHATES IN DNA REPAIR AND EFFECTS OF ASPIRIN ANALOGUES ON OESOPHAGEAL CANCER
Kilari, R. S. (2014) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton) · Cited by 2
Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal CancerPreprint
Su, C., Fennell, L., Bond, C., Kane, A. M., Kerr, G., Jardé, T., Micati, D., Engel, R. M., Chan, W. H., Hlavca, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.11.480021 · Cited by 1
Synthesis and encapsulation of 1,3,5-triazine derivatives as anticancer agent
Chalermnon, M. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.100 · Cited by 1
Cytotoxic Activity of the Cyclooxygenase Inhibitor Aspirin against Cholangiocarcinoma Cell Lines
Chai่jaroenkul, W., & Na‐Bangchang, K. (2014) · Journal of Basic and Applied Pharmacology
Dose Aspirin Inhibit the Expression of Nuclear β-CateninIn VivoAs It DoesIn VitroStudies?
Yang, D. (2013) · Intestinal Research · doi:10.5217/ir.2013.11.4.236
“즉, 아스피린 등의 약제가 인간대장암 세포주에서 β-catenin의 발현을 억제하여 선종-암종의 암화 과정의 초기 단계인 wnt/β-catenin 경로에 작용함으로써 화학예방효과를 나 타낼 것이라는 주장도 있다.(6,7) 그러나, COX-2의 주산물인 PGE2가 결국 PGE2 수용체의 한 아형인 EP2 수용체를 통해 β-catenin의 안 정화와 핵 내 이동을 촉진시켜 세포 증식과 관련된 다양한 유전자 발 현을 유도한다는 점을 고려하면,(8) β-catenin에 대한 아스피린의 작용 이 COX-2와 독립적인 것인지 혹은 COX-2 경로에 대한 작용의 결 과물인지는…”
Angiogenic effect of chemicals
Sabell, E. (2015) · Tampere University Institutional Repository (Tampere University)
Novel Cellular Targets of Aspirin in Chemoprevention studies on P53, G6PD and c-MYC
Ai, G. (2016) · Open PRAIRIE (South Dakota State University)
ANTICANCER MECHANISM OF TOLFENAMIC ACID IN COLORECTAL CANCER
Lou, Z. (2016) · University Libraries (University of Maryland) · doi:10.13016/m2tj5h
Half, E., Fokra, A., & Arber, N. (2016) · Springer eBooks · doi:10.1007/978-3-319-33889-7_15
Wang, R. (2019) · Cronfa (Swansea University) · doi:10.23889/suthesis.51919
Terapia Fotodinâmica em combinação com Ácido Acetilsalicílico
Almeida, N. A. C. P. D. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Involvement of platelets in inflammation and cancer
Mezouar, S. (2015) · theses.fr (ABES) · doi:10.70675/3209f579z7718z497fzbe5dzd52f700a4270
Metabolites and cancer metastasis
Yang, S., Shi, S., Hou, J., Zhang, J., & Su, Z. (2026) · Oncogene · doi:10.1038/s41388-026-03930-6
Metadata
- Authors
- Pathi, S., Jutooru, I., Chadalapaka, G., Nair, V., Lee, S.-O., & Safe, S.
- Affiliations
- Texas A&M University (US)
- Texas A&M Health Science Center (US)
- Corresponding author
- Safe, Stephen
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-26
- Volume
- 7
- Issue
- 10
- Pages
- e48208
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3482208
- OpenAlex
- W1968810018
- Cited by
- 127
- References
- 41
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 11 · 2017: 13 · 2016: 16 · 2015: 17 · 2014: 11 · 2013: 9
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OakTrust (Texas A&M University Libraries) (submittedVersion)
- Funders
- Texas AgriLife Research
- National Institutes of Health
- National Cancer Institute (R01CA136571)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- aspirin, colon cancer, specificity proteins, Sp1, Sp3, Sp4, salicylates, apoptosis, zinc ions, β-catenin, NF-κB, Bcl-2, survivin, vascular endothelial growth factor, c-Met, cyclin D1, tumor growth inhibition, anticancer mechanism
- MeSH terms
- Animals, Aspirin, Colonic Neoplasms, Female, Humans, Mice, Nude, Gene Expression Regulation, Neoplastic, Sp1 Transcription Factor, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Sp Transcription Factors, Sp3 Transcription Factor, Sp4 Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.